GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » EV-to-EBITDA

Pharma Mar (XMAD:PHM) EV-to-EBITDA : 137.73 (As of May. 02, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pharma Mar's enterprise value is €413.5 Mil. Pharma Mar's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €3.0 Mil. Therefore, Pharma Mar's EV-to-EBITDA for today is 137.73.

The historical rank and industry rank for Pharma Mar's EV-to-EBITDA or its related term are showing as below:

XMAD:PHM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -153.07   Med: 12.88   Max: 223.59
Current: 137.74

During the past 13 years, the highest EV-to-EBITDA of Pharma Mar was 223.59. The lowest was -153.07. And the median was 12.88.

XMAD:PHM's EV-to-EBITDA is ranked worse than
96.14% of 466 companies
in the Biotechnology industry
Industry Median: 9.35 vs XMAD:PHM: 137.74

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-02), Pharma Mar's stock price is €30.44. Pharma Mar's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.108. Therefore, Pharma Mar's PE Ratio for today is 281.85.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Pharma Mar EV-to-EBITDA Historical Data

The historical data trend for Pharma Mar's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar EV-to-EBITDA Chart

Pharma Mar Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -87.72 7.36 8.40 19.68 133.16

Pharma Mar Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.66 16.96 25.35 133.16 127.82

Competitive Comparison of Pharma Mar's EV-to-EBITDA

For the Biotechnology subindustry, Pharma Mar's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pharma Mar's EV-to-EBITDA falls into.



Pharma Mar EV-to-EBITDA Calculation

Pharma Mar's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=413.480/3.002
=137.73

Pharma Mar's current Enterprise Value is €413.5 Mil.
Pharma Mar's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Mar  (XMAD:PHM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharma Mar's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=30.44/0.108
=281.85

Pharma Mar's share price for today is €30.44.
Pharma Mar's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.108.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Pharma Mar EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pharma Mar's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Mar (XMAD:PHM) Business Description

Traded in Other Exchanges
Address
Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Pharma Mar (XMAD:PHM) Headlines